

Initial Prior Authorization

Dificid

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Dificid	fidaxomicin

Indications

FDA-Approved Indications

Dificid is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD).

Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Dificid and other antibacterial drugs, Dificid should be used only to treat infections that are proven or strongly suspected to be caused by C. difficile. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Coverage Criteria

C. difficile-Associated Diarrhea (CDAD)

Authorization may be granted for the requested drug when the patient has the diagnosis of C. difficile-associated diarrhea (CDAD) confirmed by a positive stool assay.

Duration of Approval (DOA)

- 2753-A: DOA: 10 days

References

1. Difucid [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; June 2022.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed November 4, 2024.
3. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 11/04/2024).
4. McDonald L, Gerding D, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases 2018;66 (7): e1-e48. <https://doi.org/10.1093/cid/cix1085>. Accessed November 4, 2024.